WebFeb 25, 2024 · There is no etiological treatment for Danon disease , and the management should be based on a multidisciplinary team-based approach . The management of HCM should follow the current guidelines ( 1 , 9 ), considering that in patients with Danon disease it may present earlier and may progress more rapidly compared with sarcomeric forms of … Web2 days ago · Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a devastating, pediatric heart failure condition. Rocket also has preclinical AAV-based gene therapy programs in PKP2-arrhythmogenic cardiomyopathy (ACM) and BAG3-associated dilated cardiomyopathy (DCM).
What Is Danon
WebDec 15, 2024 · Dr. Paul Thompson reflects on the diagnosis and treatment of hypertrophic cardiomyopathy and other comorbid conditions, in this column, titled "Don’t Be Thick Headed With Thick Hearts". ... also called Danon or LAMP-2 disease, and hydroxychloroquine (HCQ) treatment. HCM is the most frequent cause of thick hearts and affects 1/250 … WebNov 8, 2024 · About Danon Disease Danon Disease is a rare X-linked inherited disorder caused by mutations in the gene encoding lysosome-associated membrane protein 2 (LAMP-2), an important mediator of autophagy. dallas willard bible study
Lysosomal Storage Diseases & Disorders - Cleveland Clinic
WebPatients who suffer from Danon disease cannot correctly perform autophagy, which is a way that cells recycle proteins. We believe that our work will help in the development of new drugs to treat Danon disease. It is also possible that the drugs we discover will be useful for the treatment of other types of heart failure. WebTreatment may include medications that can be taken by mouth, injected, inserted directly into a vein (intravenous), or applied to the skin. Please consult your primary … WebApr 1, 2024 · Danon disease (DD) is a rare, X-linked monogenic cardiomyopathy caused by mutations in the LAMP2 gene which is essential for autophagy. ... Pediatric evalua- tion was preceded by treatment of two adult DD cohorts with evidence of manageable safety, LAMP2B cardiac gene and protein expression and pre- liminary clinical efficacy. In this … dallas willard and john ortberg